A new trading day began on Tuesday, with Blueprint Medicines Corp (NASDAQ: BPMC) stock price down -0.02% from the previous day of trading, before settling in for the closing price of $128.25. BPMC’s price has ranged from $73.04 to $128.34 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 50.22%. Meanwhile, its annual earnings per share averaged 34.23%. With a float of $62.30 million, this company’s outstanding shares have now reached $64.56 million.
Let’s determine the extent of company efficiency that accounts for 649 employees. In terms of profitability, gross margin is 95.84%, operating margin of -31.01%, and the pretax margin is -27.38%.
Blueprint Medicines Corp (BPMC) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Blueprint Medicines Corp is 3.67%, while institutional ownership is 106.82%. The most recent insider transaction that took place on Jun 03 ’25, was worth 340,033. In this transaction CHIEF SCIENTIFIC OFFICER of this company sold 2,659 shares at a rate of $127.88, taking the stock ownership to the 54,206 shares. Before that another transaction happened on May 27 ’25, when Company’s Director sold 5,000 for $101.14, making the entire transaction worth $505,692. This insider now owns 146,630 shares in total.
Blueprint Medicines Corp (BPMC) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 34.23% per share during the next fiscal year.
Blueprint Medicines Corp (NASDAQ: BPMC) Trading Performance Indicators
Here are Blueprint Medicines Corp’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.46, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach 0.92 in one year’s time.
Technical Analysis of Blueprint Medicines Corp (BPMC)
Looking closely at Blueprint Medicines Corp (NASDAQ: BPMC), its last 5-days average volume was 4.34 million, which is a jump from its year-to-date volume of 1.91 million. As of the previous 9 days, the stock’s Stochastic %D was 76.44%. Additionally, its Average True Range was 2.72.
During the past 100 days, Blueprint Medicines Corp’s (BPMC) raw stochastic average was set at 99.80%, which indicates a significant increase from 99.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 97.56% in the past 14 days, which was higher than the 56.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $101.38, while its 200-day Moving Average is $95.50. However, in the short run, Blueprint Medicines Corp’s stock first resistance to watch stands at $128.36. Second resistance stands at $128.50. The third major resistance level sits at $128.66. If the price goes on to break the first support level at $128.06, it is likely to go to the next support level at $127.90. Now, if the price goes above the second support level, the third support stands at $127.76.
Blueprint Medicines Corp (NASDAQ: BPMC) Key Stats
With a market capitalization of 8.29 billion, the company has a total of 64,582K Shares Outstanding. Currently, annual sales are 508,820 K while annual income is -67,090 K. The company’s previous quarter sales were 149,410 K while its latest quarter income was 500 K.
